News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New Launch of Cancer Stem Cell Products and Services at ProMab Biotechnologies, Inc.


12/13/2012 10:09:27 AM

December 13, 2012 -- ProMab Biotechnologies, Inc. your leading provider for custom monoclonal antibodies, monoclonal antibody services, ascites production, and protein expression services now offers a brand new line of our cancer stem cell products and services.

Cancer stem cells (CSCs) are hypothesized to reside within the tumor mass cell milieu, and retain certain characteristics of normal stem cells. Cancer stem cells are highly tumorigenic, in contrast to other cancer cells, persist in tumors as a distinct population, and may cause relapse by giving rise to new tumor growth with increased metastatic potential. Recent research indicates cancer stem cells display unique properties and resistance to chemotherapy and radiotherapy. This breakthrough could lead to the development of new tests for early cancer diagnosis, prognostic tests, and innovative therapeutic strategies.

Identification and isolation of cancer stem cells from either tumor cell line spheroids (tumorspheres) in vitro, or in vivo tumors, will provide valuable cell populations in order to study their origin and mechanisms of establishment, maintenance, and importantly the molecular mechanisms responsible for their conversion. ProMab’s various cancer stem cell antibodies, cancer stem cell media, cancer stem cell isolation kits and cancer stem cell markers will therefore provide the researcher with an arsenal for the development of cancer stem cell specific targeted therapies, as a means to increase survival rates amongst cancer patients in general, but especially for those at risk from tumors with high metastatic potential. See below for our cancer stem cell antibodies, cancer stem cell markers, cancer stem cell media, cancer stem cell isolation kits as well as other related products and services.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES